Key Takeaways:
Altimmune's pemvidutide faces three clinical catalysts in 2026 that will test whether a single dual-agonist molecule can address multiple liver disease markets.
Altimmune Inc. is heading into a catalyst-heavy 2026 with its lead asset pemvidutide, a balanced 1:1 dual agonist targeting both glucagon and GLP-1 receptors. The molecule is being developed across three indications — metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease — a strategy management calls "pipeline in a product."
"The company stays extremely focused. We are in an era of execution," Chief Executive Officer Jerry Durso said at the Jefferies 2026 Global Healthcare Conference.
The first milestone is the planned start of the global Phase III PERFORMA registrational study in MASH during the second half of 2026, targeting patients with moderate-to-severe liver fibrosis (F2 and F3). Altimmune has reached alignment with the US Food and Drug Administration and European regulators on key late-stage parameters. The trial will enroll about 990 biopsy-confirmed patients in Cohort 1 to support an accelerated approval efficacy assessment, with a second cohort based more heavily on non-invasive tests. Fifty-two-week data are expected in 2029.
The second catalyst is top-line Phase II data from the RECLAIM study in alcohol use disorder, expected in the third quarter of 2026. Enrollment was completed in November 2025, ahead of schedule. The study is powered around a one-day difference in heavy drinking days between pemvidutide and placebo, and will also evaluate blood markers including phosphatidylethanol and World Health Organization drinking level changes.
A third marker is enrollment completion in the RESTORE Phase II study in alcohol-associated liver disease, expected by the third quarter of 2026.
Pemvidutide's Data Foundation and Competitive Positioning
In the Phase IIb IMPACT study, pemvidutide delivered statistically significant MASH resolution without worsening fibrosis at 24 weeks, with the response sustained through 48 weeks. The company reported signs consistent with antifibrotic activity by 48 weeks, including statistically significant reductions versus placebo in non-invasive markers such as Enhanced Liver Fibrosis and liver stiffness. The 1.8 mg dose showed weight reduction through 48 weeks without plateauing, with low discontinuation rates and no serious treatment-related adverse events.
Altimmune's chief medical officer, Christophe, said the company received a "best of EASL" abstract designation for an oral presentation on 48-week data. Multiple fibrosis evaluation methods — including PRO-C3, CTX, PathAI's LiverExplore, and qFibrosis — were directionally consistent, he said. The Phase III trial will include qFibrosis as a secondary endpoint and use MASH Assist, an AI-supported tool for reading digital biopsy images.
The MASH market is crowded. Pemvidutide faces competition from Novo Nordisk's GLP-1 drugs, Eli Lilly's combination incretins, Madrigal Pharmaceuticals' Rezdiffra (the only approved MASH therapy), and Viking Therapeutics' VK2735, among others. Durso argued that GLP-1 monotherapies may become a common first-line option by the time pemvidutide could reach the market, but that tolerability and durability of treatment could differentiate pemvidutide. Discontinuation on the 1.8 mg dose in Phase II was lower than placebo, he noted.
In alcohol use disorder, pemvidutide would compete with approved options including Vivitrol and generic naltrexone and acamprosate.
Cash Runway Reduces Near-Term Funding Pressure
Altimmune held $332 million in cash, cash equivalents and short-term investments as of March 31, 2026, up from $274 million at year-end 2025. The company raised $75 million in a registered direct offering and $8 million via an at-the-market program in early 2026, then completed an oversubscribed public offering in April 2026 with $225 million in gross proceeds. Pro forma cash was roughly $535 million as of April 30.
Chief Financial Officer Greg Weaver said the balance sheet is now "north of $500 million" and expected to fund operations through the 2029 MASH readout while supporting the Phase II AUD and ALD programs. He said the company would focus on non-dilutive options going forward, including possible strategic investments, debt facility use, or an at-the-market program.
Altimmune remains a pre-revenue clinical-stage biotech with no marketed products, meaning external financing will remain central to its operating model. The company has indicated it may still raise additional funds if market conditions are favorable.
For investors, the 2026 setup is binary. Positive data from RECLAIM and successful initiation of PERFORMA could validate the multi-indication thesis and open partnering interest. A misstep in any program would likely weigh heavily on the stock given how central pemvidutide is to Altimmune's valuation. The stock recently traded at 1.24 times trailing book value, below its five-year median of 2.34 times, reflecting the market's wait-and-see posture ahead of these catalysts.
This article is for informational purposes only and does not constitute investment advice.
